SI2952177T1 - Sestavki, ki vsebujejo modulatorje receptorja sfingozin 1 fosfata (s1p) - Google Patents

Sestavki, ki vsebujejo modulatorje receptorja sfingozin 1 fosfata (s1p)

Info

Publication number
SI2952177T1
SI2952177T1 SI200832164T SI200832164T SI2952177T1 SI 2952177 T1 SI2952177 T1 SI 2952177T1 SI 200832164 T SI200832164 T SI 200832164T SI 200832164 T SI200832164 T SI 200832164T SI 2952177 T1 SI2952177 T1 SI 2952177T1
Authority
SI
Slovenia
Prior art keywords
sphingosine
phosphate
compositions
receptor modulators
modulators
Prior art date
Application number
SI200832164T
Other languages
English (en)
Slovenian (sl)
Inventor
Colleen Ruegger
Michael Ambuehl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40032615&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2952177(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI2952177T1 publication Critical patent/SI2952177T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medical Informatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
SI200832164T 2007-10-12 2008-10-09 Sestavki, ki vsebujejo modulatorje receptorja sfingozin 1 fosfata (s1p) SI2952177T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97948207P 2007-10-12 2007-10-12
EP15173766.5A EP2952177B1 (en) 2007-10-12 2008-10-09 Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators

Publications (1)

Publication Number Publication Date
SI2952177T1 true SI2952177T1 (sl) 2021-07-30

Family

ID=40032615

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200832164T SI2952177T1 (sl) 2007-10-12 2008-10-09 Sestavki, ki vsebujejo modulatorje receptorja sfingozin 1 fosfata (s1p)
SI200831476T SI2465492T1 (sl) 2007-10-12 2008-10-09 Sestavi, ki obsegajo modulatorje receptorja sfingosin 1 fosfat (S1P)

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200831476T SI2465492T1 (sl) 2007-10-12 2008-10-09 Sestavi, ki obsegajo modulatorje receptorja sfingosin 1 fosfat (S1P)

Country Status (32)

Country Link
US (6) US8673918B2 (https=)
EP (7) EP3733161A1 (https=)
JP (2) JP6034000B2 (https=)
KR (3) KR20170021904A (https=)
CN (1) CN101820916A (https=)
AR (1) AR068986A1 (https=)
AU (1) AU2008310846C1 (https=)
BR (1) BRPI0818161B8 (https=)
CA (2) CA2699788C (https=)
CL (1) CL2008003003A1 (https=)
CO (1) CO6270342A2 (https=)
DK (1) DK2952177T3 (https=)
EC (1) ECSP10010169A (https=)
ES (2) ES2545361T3 (https=)
HR (1) HRP20150838T1 (https=)
HU (2) HUE027696T2 (https=)
IL (3) IL204514B (https=)
JO (2) JOP20080436B1 (https=)
MA (1) MA31799B1 (https=)
MX (1) MX337152B (https=)
MY (1) MY159358A (https=)
NZ (1) NZ600355A (https=)
PE (2) PE20130309A1 (https=)
PL (2) PL2465492T3 (https=)
PT (2) PT2465492E (https=)
RU (1) RU2010118457A (https=)
SG (2) SG187458A1 (https=)
SI (2) SI2952177T1 (https=)
TN (1) TN2010000136A1 (https=)
TW (1) TW200927142A (https=)
WO (1) WO2009048993A2 (https=)
ZA (1) ZA201001819B (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2278960T5 (pl) 2008-03-17 2020-06-29 Actelion Pharmaceuticals Ltd. Schemat dawkowania dla selektywnego agonisty receptora sip1
KR101618906B1 (ko) * 2008-08-18 2016-05-09 노파르티스 아게 말초 신경병증의 치료를 위한 화합물
JP5657565B2 (ja) * 2008-12-22 2015-01-21 ノバルティス アーゲー Ｓ１ｐ受容体アゴニストの投与レジメン
TW201028143A (en) * 2008-12-22 2010-08-01 Novartis Ag Dosage regimen for a S1P receptor agonist
EP2560618A1 (en) * 2010-04-22 2013-02-27 Ratiopharm GmbH Melt-granulated fingolimod
EA201291096A1 (ru) * 2010-04-22 2013-04-30 Рациофарм Гмбх Финголимод в форме твердого раствора
CN101973898B (zh) * 2010-09-09 2013-06-19 南京明生医药技术有限公司 2-对辛基苯乙基-2-氨基丙二醇衍生物及其应用
JP6111202B2 (ja) * 2011-01-07 2017-04-05 ノバルティス アーゲー 免疫抑制製剤
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
ES2388273B1 (es) * 2011-03-16 2013-10-01 Consejo Superior De Investigaciones Científicas (Csic) Uso de inhibidores de receptores de s1p para el tratamiento de la estenosis aórtica calcificada
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
US9186333B2 (en) * 2011-08-01 2015-11-17 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions of fingolimod
BR112014009141A8 (pt) * 2011-10-21 2017-06-20 Novartis Ag regime de dosagem para um modulador ou agonista do receptor s1p
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
JP2014129238A (ja) * 2012-12-28 2014-07-10 Lion Corp エトドラク含有固形製剤
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
EP2996681B1 (en) * 2013-05-13 2019-12-18 Synthon B.V. Pharmaceutical composition comprising fingolimod
EP3027174B1 (en) 2013-07-29 2019-07-24 Aizant Drug Research Solutions Private Limited Pharmaceutical compositions of fingolimod
US20150141520A1 (en) * 2013-11-18 2015-05-21 Chandrasekhar Kandi Stabilized pharmaceutical compositions of fingolimod and process for preparation thereof
JP6602779B2 (ja) 2014-02-13 2019-11-06 インサイト・コーポレイション Ｌｓｄ１阻害剤としてのシクロプロピルアミン類
EP3105218B1 (en) 2014-02-13 2019-09-25 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
EP3105219B9 (en) 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
ES2865451T3 (es) * 2014-04-10 2021-10-15 Novartis Ag Formulación inmunosupresora
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016026461A1 (en) * 2014-08-22 2016-02-25 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
RU2017112748A (ru) * 2014-11-17 2018-12-19 Арно Терапьютикс, Инк. Композиции онапристона пролонгированного действия и способы
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
EP3247341A4 (en) * 2015-01-20 2018-12-19 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
JP6680297B2 (ja) * 2015-04-28 2020-04-15 アステラス製薬株式会社 経口投与用医薬組成物
MY189367A (en) 2015-08-12 2022-02-08 Incyte Corp Salts of an lsd1 inhibitor
RU2639424C2 (ru) * 2015-09-15 2017-12-21 Закрытое Акционерное Общество "Биокад" Твердая пероральная фармацевтическая композиция S1P-агониста или его фармацевтически приемлемой соли, способы ее получения и способы лечения и снижения частоты клинических обострений рассеянного склероза
EP3355863A4 (en) * 2015-10-02 2019-06-19 Mylan, Inc STABLE FORMULATIONS OF FINGOLIMOD
TWI833686B (zh) * 2016-04-22 2024-03-01 美商英塞特公司 Lsd1 抑制劑之調配物
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
EP3419607B1 (en) 2017-03-29 2019-11-20 Deva Holding Anonim Sirketi Stable formulations of fingolimod
JP7365409B2 (ja) 2018-06-28 2023-10-19 エイアールエックス エルエルシー 溶解性単位用量膜構造物を製造するための分配方法
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
US12116285B2 (en) 2018-10-05 2024-10-15 Fuji Chemical Industries Co., Ltd. Porous silica particle composition
CN117202893A (zh) * 2021-04-14 2023-12-08 株式会社Lg化学 包含鞘氨醇-1-磷酸受体激动剂的可直接压缩的药物组合物
CN117120038A (zh) * 2021-04-14 2023-11-24 株式会社Lg化学 包含鞘氨醇-1-磷酸受体激动剂的固体制剂的制备方法
US20240207242A1 (en) * 2021-04-14 2024-06-27 Lg Chem, Ltd. Pharmaceutical composition comprising sphingosine-1-phosphate receptor agonist with controlled particle size
WO2024126409A1 (en) 2022-12-12 2024-06-20 Synthon B.V. Pharmaceutical composition of siponimod

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69321823T2 (de) 1992-10-21 1999-06-02 Taito Co., Ltd., Tokio/Tokyo 2-amino-1, 3- propandiolverbindung und immunosuppressium
EP0778263B1 (en) 1994-08-22 2002-01-09 Welfide Corporation Benzene compound and medicinal use thereof
US5616621A (en) * 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
WO1997024112A1 (en) 1995-12-28 1997-07-10 Yoshitomi Pharmaceutical Industries, Ltd. External preparation
KR20000075745A (ko) 1997-02-27 2000-12-26 가마후라 아키오 의약 조성물
ES2240868T3 (es) 1997-04-04 2005-10-16 Mitsubishi Pharma Corporation Compuesto de 2-aminopropano -1,3-diol, su uso farmaceutico e intermedios en su sintesis.
JP4627356B2 (ja) 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
CN1328387C (zh) 2000-07-13 2007-07-25 三共株式会社 氨基醇衍生物
EP1315735A4 (en) 2000-08-31 2005-04-06 Merck & Co Inc Phosphate derivatives as immunoregulatory compounds
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
CA2461212C (en) 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
DE60235900D1 (de) 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
JP4430941B2 (ja) 2002-01-18 2010-03-10 メルク エンド カムパニー インコーポレーテッド Ｅｄｇ受容体作動薬
JP4571497B2 (ja) 2002-09-19 2010-10-27 杏林製薬株式会社 アミノアルコール誘導体とその付加塩及び免疫抑制剤
BRPI0407658A (pt) 2003-02-18 2006-02-21 Kyorin Seiyaku Kk derivados de ácido aminofosfÈnico, seus sais e hidratos que atuam como moduladores de receptor de s1p e agente farmacêutico
PE20130200A1 (es) * 2003-04-08 2013-03-09 Novartis Ag Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar
TW200503783A (en) 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
FR2854549B1 (fr) 2003-05-06 2005-06-24 Actis Ets Tete pour l'equipement d'un bras de robot destine a realiser une operation d'ebavurage ou de cardage
CL2004001120A1 (es) 2003-05-19 2005-04-15 Irm Llc Compuestos derivados de amina sustituidas con heterociclos, inmunosupresores; composicion farmaceutica; y uso para tratar enfermedades mediadas por interacciones de linfocito, tales como enfermedades autoinmunes, inflamatorias, infecciosas, cancer.
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
PL1643983T3 (pl) 2003-06-24 2010-10-29 Univ Connecticut Sposoby hamowania przepuszczalności naczyń krwionośnych i apoptozy
ATE449069T1 (de) 2003-08-28 2009-12-15 Novartis Pharma Gmbh Aminopropanolderivate
AU2004271804B2 (en) * 2003-09-12 2011-01-06 Newron Sweden Ab Treatment of disorders of the nervous system
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
US8633161B2 (en) 2005-03-24 2014-01-21 The Ohio State University Research Foundation Therapeutic agents for the treatment of leukemia
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
HUE046441T2 (hu) * 2006-09-26 2020-02-28 Novartis Ag S1P modulátort tartalmazó gyógyászati készítmények

Also Published As

Publication number Publication date
IL277999A (en) 2020-11-30
TW200927142A (en) 2009-07-01
JOP20080436B1 (ar) 2023-03-28
EP3120833A1 (en) 2017-01-25
PT2952177T (pt) 2021-04-26
RU2016138157A (ru) 2018-12-13
WO2009048993A3 (en) 2010-05-06
IL255737A (en) 2018-01-31
CA2925175A1 (en) 2009-04-16
EP2465492A1 (en) 2012-06-20
US9399066B2 (en) 2016-07-26
BRPI0818161B1 (pt) 2020-12-22
KR101710845B1 (ko) 2017-02-27
HRP20150838T1 (hr) 2015-11-06
PE20130309A1 (es) 2013-03-30
CL2008003003A1 (es) 2009-05-15
ZA201001819B (en) 2010-12-29
HUE027696T2 (en) 2016-10-28
US8673918B2 (en) 2014-03-18
SG187458A1 (en) 2013-02-28
RU2016138157A3 (https=) 2020-02-10
KR20100091179A (ko) 2010-08-18
US20150165046A1 (en) 2015-06-18
US20140142192A1 (en) 2014-05-22
SI2465492T1 (sl) 2015-12-31
HK1213768A1 (en) 2016-07-15
AU2008310846B2 (en) 2012-06-21
CO6270342A2 (es) 2011-04-20
JP2015091822A (ja) 2015-05-14
JOP20210187A1 (ar) 2021-07-08
ES2545361T3 (es) 2015-09-10
PL2465492T3 (pl) 2015-11-30
IL204514B (en) 2018-01-31
WO2009048993A2 (en) 2009-04-16
PE20090799A1 (es) 2009-07-20
EP3733161A1 (en) 2020-11-04
CA2699788C (en) 2016-06-14
PT2465492E (pt) 2015-10-15
BRPI0818161A2 (pt) 2017-05-16
NZ600355A (en) 2013-02-22
HUE053835T2 (hu) 2021-07-28
EP2952177B1 (en) 2021-01-20
EP2465492B1 (en) 2015-07-01
RU2010118457A (ru) 2011-11-20
US20100267675A1 (en) 2010-10-21
JP6034000B2 (ja) 2016-11-30
ES2864671T3 (es) 2021-10-14
MX2010003925A (es) 2010-05-05
US20160296481A1 (en) 2016-10-13
US20170368001A1 (en) 2017-12-28
TN2010000136A1 (en) 2011-09-26
EP2653154A1 (en) 2013-10-23
KR101600098B1 (ko) 2016-03-04
EP2952177A1 (en) 2015-12-09
SG10201800085XA (en) 2018-02-27
AU2008310846C1 (en) 2022-10-06
CN101820916A (zh) 2010-09-01
AU2008310846A1 (en) 2009-04-16
MA31799B1 (fr) 2010-10-01
PL2952177T3 (pl) 2021-07-19
AR068986A1 (es) 2009-12-23
JP2011500583A (ja) 2011-01-06
EP3733162A1 (en) 2020-11-04
ECSP10010169A (es) 2010-06-29
IL255737B (en) 2020-10-29
KR20170021904A (ko) 2017-02-28
EP2209493A2 (en) 2010-07-28
US20170151195A1 (en) 2017-06-01
MY159358A (en) 2016-12-30
BRPI0818161B8 (pt) 2021-05-25
MX337152B (es) 2016-02-15
DK2952177T3 (da) 2021-04-26
KR20160025633A (ko) 2016-03-08
CA2699788A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
IL277999A (en) Compounds containing modulators of the sphingosine 1 phosphate (S1P) receptor
HUS2000038I1 (hu) Szfingozin foszfát receptor új modulátorai
PL2959894T3 (pl) Modulatory receptora s1p do leczenia stwardnienia rozsianego
SI3103448T1 (sl) Farmacevtski sestavek, ki vsebuje modulator S1P
IL219692A0 (en) Selective heterocyclic sphingosine 1 phosphate receptor modulators
ZA201000585B (en) 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (s1p) receptor for the treatment of multiple sclerosis
PL2038290T3 (pl) Modulatory receptora Toll-podobnego 7
IL196226A0 (en) Phosphonate and phosphinate compounds and pharmaceutical compositions containing the same
AP2010005247A0 (en) Composition for regulating lipid metabolism
IL209306A (en) Compounds 1, 2, 4 - Oxadiazole as modulators of sphingosine phosphate receptors
EP2178539A4 (en) PHOSPHOLIPIDE COMPREHENSIVE COMPOSITIONS
HK1143526A (en) Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
GB0722340D0 (en) Sphingosine-1-phosphate (S1P) receptor compounds
GB0610311D0 (en) Bisphosphonate formulation
HK1143359A (en) 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (s1p) receptor for the treatment of multiple sclerosis